本文選題：早期乳腺浸潤性導管癌　切入點：miR-10b　出處：《新疆醫(yī)科大學》2017年碩士論文　論文類型：學位論文

【摘要】：目的:探討miR-10b表達與乳腺早期浸潤性導管癌分子亞型兩者相關性。方法:針對305例乳腺早期浸潤性導管癌中的miR-10b的表達使用原位分子雜交技術進行檢測,乳腺早期浸潤性導管癌中雌激素受體(ER-α)、孕激素受體(PR)、人類表皮生長因子受體-2(Her-2)表達給予免疫組化檢測,根據(jù)ER-α、PR及Her-2分為四個分子亞型。分析不同臨床指標間miR-10b表達的差異性使用Pearson卡方檢驗方法;Spearman秩合檢驗方法分析早期乳腺浸潤性導管癌中miR-10b、分子亞型、ER-α、PR、Her-2和淋巴結(jié)狀態(tài)相互關聯(lián)性。計算累計無瘤生存時間用Kaplan-Meier法;分析中位無瘤生存時間使用Log-rank檢驗進行。結(jié)果:miR-10b表達與患者年齡、ER-α、PR及復發(fā)轉(zhuǎn)移,差異具有統(tǒng)計學意義(P0.05);與月經(jīng)狀態(tài)、腫瘤大小、臨床分期及總淋巴、化療以及放療、內(nèi)分泌治療,差異無統(tǒng)計學意義(P0.05)。早期乳腺浸潤性導管癌中mi R-10b表達與不同分子亞型中具有顯著性差異(P0.05),miR-10b與分子亞型呈正相關,miR-10b陽性表達中Basal-like型所占比例明顯高于其它三種分子亞型。mi R-10b陽性表達無瘤生存率顯著下降,預后差。早期乳腺浸潤性導管癌四種分子亞型中,Luminal B型差異具有統(tǒng)計學意義(P0.05);Luminal A型、Her-2過表達型、Basal-like型經(jīng)Log-rank檢驗,差異不具有統(tǒng)計學意義(P0.05)。結(jié)論:miR-10b在乳腺早期浸潤性導管癌中的陽性表達與ER-α、年齡及復發(fā)轉(zhuǎn)移具有一定的相關性,且mi R-10b陽性表達是其分子亞型的預后不良指標,miR-10b表達對其預后判斷提供幫助。
[Abstract]:Objective: to investigate the relationship between the expression of miR-10b and molecular subtypes of early invasive ductal carcinoma of breast. Methods: the expression of miR-10b in 305 cases of early invasive ductal carcinoma of breast was detected by in situ molecular hybridization. The expression of estrogen receptor ER- 偽, progesterone receptor, human epidermal growth factor receptor-2 and human epidermal growth factor receptor-2 Her-2 in early invasive ductal carcinoma of the breast were detected by immunohistochemistry. According to ER- 偽 -PR and Her-2, there are four molecular subtypes. To analyze the difference of miR-10b expression among different clinical indexes, Pearson chi-square test was used to analyze miR-10b, molecular subtype ER- 偽 -PRN Her-2 and lymphadenoid ductal carcinoma in early stage of breast invasive ductal carcinoma by using Spearman rank test. The cumulative tumor-free survival time was calculated by Kaplan-Meier method. Log-rank test was used to analyze the median tumor-free survival time. Results the expression of micromiR-10b was significantly different from age, ER- 偽 PR, recurrence and metastasis, and with menstrual status, tumor size, clinical stage, total lymph node, chemotherapy and radiotherapy. Endocrine therapy, The expression of miR-10b in early invasive ductal carcinoma of breast was significantly different from that in different molecular subtypes. There was a positive correlation between the expression of miR-10b and the molecular subtypes. The proportion of Basal-like type in the positive expression of P0.05 and molecular subtypes was significantly higher than that of the other three subtypes. The tumor-free survival rate of subtype .mi R-10b was significantly decreased. The prognosis was poor. Among the four molecular subtypes of early invasive ductal carcinoma of breast, the difference of Luminal B was statistically significant. Conclusion the positive expression of 1% miR-10b in early invasive ductal carcinoma of the breast is correlated with ER- 偽, age, recurrence and metastasis. The positive expression of miR-10b was a poor prognostic marker of its molecular subtype, and the expression of miR-10b was helpful to its prognosis.
【學位授予單位】：新疆醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R737.9

【相似文獻】

相關期刊論文 前1條

1 謝子鈞;陳剛;黃健;李子俊;;血漿miR-10b對食管癌的診斷價值[J];廣東醫(yī)學;2013年16期

相關博士學位論文 前1條

1 郭晨明;早期乳腺浸潤性導管癌miR-10b的表達與臨床病理因素、分子亞型及預后的初步研究[D];新疆醫(yī)科大學;2016年

相關碩士學位論文 前4條

1 鄭春雷;MiR-10b在胰腺癌中的表達及臨床意義[D];鄭州大學;2015年

2 張夢曦;miR-10b調(diào)控HOXD10在食管癌侵襲、轉(zhuǎn)移中的研究[D];河南科技大學;2015年

3 吳楠;MiR-10b表達與早期乳腺浸潤性導管癌分子亞型相關性分析[D];新疆醫(yī)科大學;2017年

4 姜帥;miR-10b，miR-195在乳腺浸潤性導管癌中的表達變化及意義[D];青島大學;2014年

，

本文編號：1606467